Pharmacovigilance Department
Osaka, 540-0021, Japan
NCT Number: NCT04812379
To investigate the safety for an observation period of 52 weeks with use of Abilify prolonged release aqueous suspension for intramuscular (IM) injection in patients with bipolar I disorder for prevention of recurrence/relapse of mood episodes in the routine clinical setting. The early stage safety after the switching from oral aripiprazole to this IM injection is investigated including extrapyramidal syndrome and malignant syndrome. Information regarding efficacy is collected as well.
Looking for future studies?
Notify MeAll sexes
Observational
Osaka, 540-0021, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-
Exclusion criteria
The usual dose in adults is 400 mg of aripiprazole administered intramuscularly in the gluteal or deltoid muscle as a single dose once every 4 weeks. The dose may be decreased to 300 mg based on the patient's symptoms and tolerability.
Time frame: 52 weeks from the start date of Abilify prolonged release aqueous suspension for IM injection therapy
Any untoward medicinal occurrence in a patient or clinical study subject administered a Medicinal Product and which does not necessarily have a causal relationship with this treatment (ICH-E2A Guideline).
An Adverse Event can therefore be any unfavorable and unintended sign (e.g. abnormal laboratory finding), symptom, or disease temporally associated with the use of a Medicinal Product (Abilify Prolonged Release Aqueous Suspension), whether or not it is considered causally related to the Medicinal Product.
Time frame: 52 weeks from the start date of Abilify prolonged release aqueous suspension for IM injection therapy
Collecting any Situations related to the use of an Otsuka product which may or may not be associated with an adverse event:
(Safety Information)
Time frame: 52 weeks from the start date of Abilify prolonged release aqueous suspension for IM injection therapy
Collecting any type of off-Label Use that refers to situations where a product is intentionally used for a medical purpose not in accordance with the authorized product information. Off-label use also includes the intentional use in non-authorized population categories not indicated in the label.
(Safety Information)
Time frame: 52 weeks from the start date of Abilify prolonged release aqueous suspension for IM injection therapy
Collecting the number of any adverse drug experience/event occurring at any dose which
(Safety Information)
Time frame: 52 weeks from the start date of Abilify prolonged release aqueous suspension for IM injection therapy
Collecting the number of non-serious Adverse Events
(Safety Information)
Time frame: 52 weeks from the start date of Abilify prolonged release aqueous suspension for IM injection therapy
Collecting the number of patients who recurrence/relapse of Mood Episodes (Efficacy Information)
Otsuka Pharmaceutical Co., Ltd.
Industry
Abilify Prolonged Release Aqueous Suspension for Intramuscular Injection Specified Drug-use Results Survey (Prevention of Recurrence/relapse of Mood Episodes in Bipolar I Disorder)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04358900
Bipolar Disorder, Bipolar Disorder I
Chicago, Illinois, United States
View Trial DetailsNCT05870501
Anhedonia, Behavior
London, United Kingdom
View Trial DetailsNCT03692910
Bipolar Disorder, Bipolar Disorder I
Little Rock, Arkansas, United States
View Trial DetailsNCT05683431
Behavior, Bipolar Affective Disorder
Chicago, Illinois, United States
View Trial Details